These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26976975)

  • 1. NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors.
    Kolodziej MA; Weischer C; Reinges MH; Uhl E; Weigand MA; Schwarm FP; Schänzer A; Acker T; Quint K; Uhle F; Stein M
    Anticancer Res; 2016 Mar; 36(3):887-97. PubMed ID: 26976975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.
    Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M;
    Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.
    Hsu CY; Ho HL; Lin SC; Chang-Chien YC; Chen MH; Hsu SP; Yen YS; Guo WY; Ho DM
    J Neurooncol; 2015 Mar; 122(1):179-88. PubMed ID: 25575938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
    Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
    Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
    Wang W; Zhang L; Wang Z; Yang F; Wang H; Liang T; Wu F; Lan Q; Wang J; Zhao J
    Oncotarget; 2016 Oct; 7(43):69991-69999. PubMed ID: 27588397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.
    Balańa C; Carrato C; Ramírez JL; Cardona AF; Berdiel M; Sánchez JJ; Tarón M; Hostalot C; Musulen E; Ariza A; Rosell R
    Clin Transl Oncol; 2011 Sep; 13(9):677-85. PubMed ID: 21865140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
    McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
    Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.